Federal Register Notice: FDA has determined the regulatory review period for Actelion Pharmaceuticals’ Opsumit (macitentan) is 1,935 days for extending a patent which claims the human drug product. Opsumit is indicated for treating pulmonary arterial hypertension to delay disease progression. To view this notice, click here.
